Your browser doesn't support javascript.
loading
Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model.
Nakajima, Misaki; Nagase, Shotaro; Iida, Manami; Takeda, Shuji; Yamashita, Mayo; Watari, Akihiro; Shirasago, Yoshitaka; Fukasawa, Masayoshi; Takeda, Hiroyuki; Sawasaki, Tatsuya; Yagi, Kiyohito; Kondoh, Masuo.
Afiliação
  • Nakajima M; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Nagase S; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Iida M; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Takeda S; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Yamashita M; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Watari A; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Shirasago Y; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Fukasawa M; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Takeda H; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Sawasaki T; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Yagi K; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
  • Kondoh M; Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (M.N., S.N., M.I., M.Y., A.W., K.Y., M.K.); Asubio Pharma Co., Ltd., Hyogo, Japan (S.T.); Department of Biochemistry and Cell Biology, National Institute of Infectious Disease
J Pharmacol Exp Ther ; 354(3): 440-7, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26139628
ABSTRACT
Tight junctions (TJs) are complex biochemical structures that seal the intercellular space and prevent the free movement of solutes across epithelial cell sheets. Modulating the TJ seal is a promising option for increasing the transdermal absorption of drugs. Within TJs, the binding of the claudin (CLDN) family of tetratransmembrane proteins through cis- and trans-interactions is an integral part of seal formation. Because epidermal TJs contain CLDN-1 and CLDN-4, a binder for these CLDNs may be a useful modulator of the permeability of the epidermal barrier. Here, we investigated whether m19, which can bind to CLDN-1/-4 (also CLDN-2/-5), modulates the integrity of epidermal TJs and the permeability of cell sheets to solutes. Treatment of normal human epidermal keratinocytes (NHEKs) with the CLDN binder reduced the integrity of TJs. A CLDN-1-specific binder (a monoclonal antibody, clone 7A5) also weakened the TJ seal in NHEKs. Although m19 attenuated the TJ barrier in human intestinal epithelial cells (Caco-2), 7A5 did not. Treatment of NHEKs with 7A5 enhanced permeation of a paracellular permeation marker. These findings indicate that CLDN-1 is a potential target for modulating the permeability of the epidermis, and that our CLDN-1 binder is a promising candidate molecule for development as a dermal absorption enhancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ligação Proteica / Queratinócitos / Claudina-1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ligação Proteica / Queratinócitos / Claudina-1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article